Cetera Advisors LLC Has $340,000 Position in Boston Scientific Co. (BSX)

Cetera Advisors LLC lessened its stake in shares of Boston Scientific Co. (NYSE:BSX) by 24.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,654 shares of the medical equipment provider’s stock after selling 3,048 shares during the quarter. Cetera Advisors LLC’s holdings in Boston Scientific were worth $340,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. We Are One Seven LLC acquired a new stake in Boston Scientific during the 4th quarter valued at $27,000. Ipswich Investment Management Co. Inc. acquired a new stake in Boston Scientific during the 4th quarter valued at $28,000. Athena Capital Advisors LLC acquired a new stake in Boston Scientific during the 4th quarter valued at $28,000. CWM LLC increased its holdings in Boston Scientific by 54.3% during the 4th quarter. CWM LLC now owns 1,020 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 359 shares in the last quarter. Finally, West Oak Capital LLC increased its holdings in Boston Scientific by 40.0% during the 4th quarter. West Oak Capital LLC now owns 1,050 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 300 shares in the last quarter. Institutional investors and hedge funds own 92.00% of the company’s stock.

NYSE BSX opened at $38.66 on Tuesday. The firm has a market capitalization of $53.37 billion, a PE ratio of 26.30, a PEG ratio of 2.19 and a beta of 0.87. Boston Scientific Co. has a 52 week low of $26.42 and a 52 week high of $41.00. The company has a quick ratio of 0.54, a current ratio of 0.76 and a debt-to-equity ratio of 0.55.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 6th. The medical equipment provider reported $0.39 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.02. The company had revenue of $2.56 billion during the quarter, compared to analysts’ expectations of $2.57 billion. Boston Scientific had a return on equity of 25.92% and a net margin of 17.01%. The business’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same period last year, the firm earned $0.34 EPS. As a group, equities research analysts expect that Boston Scientific Co. will post 1.56 EPS for the current year.

In related news, EVP David A. Pierce sold 1,357 shares of Boston Scientific stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $40.25, for a total transaction of $54,619.25. Following the completion of the sale, the executive vice president now directly owns 38,940 shares of the company’s stock, valued at $1,567,335. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP David A. Pierce sold 14,739 shares of Boston Scientific stock in a transaction on Monday, March 18th. The stock was sold at an average price of $39.13, for a total value of $576,737.07. Following the sale, the executive vice president now directly owns 38,601 shares of the company’s stock, valued at $1,510,457.13. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 361,138 shares of company stock valued at $14,316,850. 0.73% of the stock is owned by insiders.

BSX has been the subject of a number of recent analyst reports. Zacks Investment Research cut Boston Scientific from a “hold” rating to a “sell” rating in a report on Monday, December 31st. Needham & Company LLC reaffirmed a “buy” rating and set a $43.00 price target on shares of Boston Scientific in a report on Wednesday, February 6th. Credit Suisse Group initiated coverage on Boston Scientific in a report on Monday, December 17th. They set an “outperform” rating and a $42.00 price target for the company. Canaccord Genuity reaffirmed a “buy” rating and set a $45.00 price target on shares of Boston Scientific in a report on Monday, February 11th. Finally, Guggenheim reaffirmed a “buy” rating and set a $48.00 price target on shares of Boston Scientific in a report on Friday, February 8th. Three equities research analysts have rated the stock with a hold rating, twenty-two have given a buy rating and two have assigned a strong buy rating to the company. Boston Scientific currently has a consensus rating of “Buy” and a consensus target price of $40.54.

TRADEMARK VIOLATION WARNING: “Cetera Advisors LLC Has $340,000 Position in Boston Scientific Co. (BSX)” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://sportsperspectives.com/2019/04/02/cetera-advisors-llc-has-340000-position-in-boston-scientific-co-bsx.html.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Article: Is it Safe to Invest in Commodities?

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.